Biotech News

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

UroGen Pharma (URGN)UroGen Pharma2026-06-25 13:46 ESTFDA / regulatory

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J Code

Open original release

Related news

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

URGNUroGen Pharma2026-06-25 13:46 EST

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at Upcoming Investor Conferences

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

URGNUroGen Pharma2026-06-25 13:46 EST

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

View all latest news

UroGen Pharma

UroGen Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

URGNUroGen Pharma2026-06-26 09:32 EST

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

URGNUroGen Pharma2026-06-26 09:32 EST

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

URGNUroGen Pharma2026-06-26 09:32 EST

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

URGNUroGen Pharma2026-06-26 09:32 EST

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

URGNUroGen Pharma2026-06-26 09:32 EST

UroGen Pharma to Present at Upcoming Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States